An observational study in Schizophrenia, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Schizophrenia by Bristol-Myers Squibb — 8 open to participants now, 9 under way, 4 of them phase 3. Schizophrenia · Bristol-Myers Squibb.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, this one is one of 7 that started in 2026, is one of 4 observational ones, and was the 21st registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →8 of the 21 studies in Schizophrenia by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Argentina, Bulgaria and 4 more countries
Ages 18–65
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in United States, Australia, Canada and 8 more countries
Ages 5–17
Bristol-Myers Squibb · Sites in United States
Ages 18+
Bristol-Myers Squibb · Sites in United States, Colombia, Japan and 1 more country
Ages 13–17
Bristol-Myers Squibb · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 178 across 507 observational studies indexed under Schizophrenia.
Median enrollment 202 across the 17 interventional studies, 2,250 across the 4 observational. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
2 of the studies in Schizophrenia by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07061288Bristol-Myers SquibbA Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | 2027-06-21 |
| NCT07783373Bristol-Myers SquibbLong-Term Real-World Safety of Cobenfy in Adults With Schizophrenia | 2027-09-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Schizophrenia by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the long-term real-world safety of xanomeline-trospium chloride in adults with schizophrenia receiving routine clinical care in the United States.
The study will include adults in the United States with schizophrenia who initiate xanomeline-trospium chloride or comparator oral antipsychotics between 27 September 2024 and 26 September 2027.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Either:
Exclusion Criteria:
Participants who initiate xanomeline-trospium chloride treatment
Drug: xanomeline-trospium chloride
Participants who initiate first-generation or second-generation oral antipsychotics
Drug: Oral antipsychotics
As per product label
As per product label
Number of participants with incident urinary retention
Time frame: Up to 3-years
Number of participants with incident biliary disorders
Time frame: Up to 3-years
Number of participants with incident sinus tachycardia
Time frame: Up to 3-years
Number of participants with incident syncope resulting from orthostatic hypotension
Time frame: Up to 3-years
Number of participants with incident hypertension
Time frame: Up to 3-years
Number of participants with incident liver injury
Time frame: Up to 3-years
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.